Xarelto rivaroxaban regulatory update

The European Commission approved Xarelto rivaroxaban from Bayer to treat pulmonary embolism (PE) and to prevent recurrent deep vein thrombosis (DVT) and PE. The oral Factor Xa inhibitor is approved in Europe to treat DVT, to prevent recurrent DVT and PE following an acute DVT, to prevent venous thromboembolic events (VTE) in adult patients undergoing hip or knee replacement surgery and to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). ...